Abstract:Background: In the era of sentinel node biopsy (SNB), mainly aimed at local control, the axillary dissection (AD) was performed for breast cancer with positive node. It was argued that only level I/II lymph nodes dissection might be inadequate because nodes involvement was found in level III and interpectoral region when axillary node was positive. It is necessary to assess the extent of AD after modern preoperative axillary staging. The aim of this study was to investigate the incidence and associated factors of node involvement in level III/interpectoral region. Methods: A consecutive series of 338 core needle biopsy confirmed T0-2 invasive breast cancer cases were included in this study. Axillary node metastases were proved by ultrasound guided needle biopsy (NB) if ultrasonographic abnormal node was detected prior to SNB or by SNB if no abnormal node was detected. Cases of negative NB but positive SNB with image abnormal node were excluded. Prior to AD included level III and interpectoral lymph nodes, 4 to 8 cycles of neoadjuvant chemotherapy with anthrocyclin and/or taxane regimen were completed for each case. The chi-square test was used to determine the relation between level III/interpectoral lymph nodes metastases and clinicopathological factors. Multivariate logistic regression was analyzed for covariate selection. Results: A median of 19 axillary nodes was harvested per case (range: 5-46, average: 19.2). The pathologic complete response rate of axillary nodes was 35.3% (70/198) in NB positive subgroup. Level III and interpectoral lymph nodes were harvested in 76.9% (260/338) of cases (range: 1-8, average: 1.9, median: 1) and 49.7% (168/338) of cases (range: 1-10, average: 1.6, median: 1), respectively. The incidence of positive level III and interpectoral lymph nodes were 8.9% (30/338) and 8.9% (30/338), respectively. Node involvement of level III/interpectoral region was found in 13.3% (45/338) of these cases. The incidence of node involvement in level III/interpectoral region of NB positive subgroup (14.6%, 29/198) was not significantly higher compared with SNB positive subgroup (11.4%, 16/140, P=0.391). Increasing tumor size was significantly correlated with increasing likelihood of node involvement in level III/interpectoral region (T0-1: 6.3% vs T2: 16.7%, P=0.008). In SNB positive T0-1 subgroup, there was no positive node found in level III/interpectoral region. Multivariate analysis showed that tumor size was the only independent factors predicting node involvement in level III/interpectoral region (OR=3.488, 95%CI:1.427-8.528, P=0.006). Conclusions: The incidence of node involvement in level III/interpectoral region was 13.3% of nodes positive T0-2 breast cancer treated with neoadjuvant chemotherapy. Tumor size may be the predictor of node involvement in this region. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-01-27.

Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.

Abstract P1-01-27: Level III and Interpectoral Lymph Nodes Involvement in Breast Cancer with Positive Axillary Lymph Nodes after Neoadjuvant Chemotherapy

Incidence and Risk Factors of Lymph Node Metastasis in Breast Cancer Patients Without Preoperative Chemoradiotherapy and Neoadjuvant Therapy: Analysis of SEER Data.

The Impact of Total Retrieved Lymph Nodes on Staging and Survival of Patients with Pt3 Gastric Cancer.

High Risk For Non-Sentinel Node Metastasis In Breast Cancer Patients With Sentinel Node Metastases

Risk Factors and Prognostic Significance of Level Ⅲ Axillary Lymph Node Metastasis in Breast Cancer Patients after Neoadjuvant Chemotherapy

Prediction of the number of positive axillary lymph nodes according to sentinel lymph node involvement and biological subtypes in patients receiving neoadjuvant chemotherapy

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy.

Exploration of the Extent of Axillary Dissection for Patients with Node Positive Primary Breast Cancer

Effect of Neoadjuvant Chemotherapy in Treatment of Locally Advanced Breast Cancer with Cytologically Proven Axillary Node Metastases

Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells after Neoadjuvant Chemotherapy for Breast Cancer

Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy

Lymph Node Counts and Ratio in Axillary Dissections Following Neoadjuvant Chemotherapy for Breast Cancer: A Better Alternative to Traditional Pn Staging

The Role of Level III Dissection in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy-A Prospective Study

Axillary Lymph Node Dissection in Triple-Negative or HER2-positive Breast Cancer Patients with Clinical N2 Achieving Pathological Complete Response after Neoadjuvant Therapy: is It Necessary?

Number of Negative Lymph Nodes As a Prognostic Factor for Ypn0-N1 Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Nodal Response to Neo-Adjuvant Systemic Therapy Predicts Prognosis of Cn3c Breast Cancer Patients Receiving Multidisciplinary Therapy

Response to neoadjuvant chemotherapy in the breast predicts axillary nodal status.

Risk factors for non-sentinel lymph node metastasis in patients after neoadjuvant chemotherapy]

[Impact of Response of Positive Axillary Nodes to Neoadjuvant Chemotherapy on Breast Cancer Survival].

Indications for Postmastectomy Radiotherapy in Breast Cancer Patients with 1 -3 Positive Axillary Nodes